Treatment with dapagliflozin reduced the risk of death or worsening heart failure by 28% compared with standard of care. Dapagliflozin reduced the risk of death or worsening heart failure (HF) in ...
Hosted on MSN
Dapagliflozin found to be safe and effective in elderly patients with heart failure undergoing valve replacement
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...
Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...
In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients
In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, although positive effects ...
CHICAGO, IL—High-risk older patients with a history of heart failure (HF) who are undergoing transcatheter aortic valve implantation have better outcomes when taking dapagliflozin, results from the ...
Hosted on MSN
On dapagliflozin for diabetes or heart failure? NHS issues warning over 3 symptoms patients should not ignore
The NHS has urged people using a commonly prescribed medication to seek urgent medical advice if they notice any of three specific symptoms. These are linked to some of the more serious complications ...
Dapagliflozin safe and effective in elderly patients with heart failure undergoing valve replacement
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback